Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jtho.2019.06.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of RET-TKI in advanced RET-rearranged non-small cell lung cancer in China: a real-world retrospective chart review.
BMC Cancer
November 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Background: Selective RET inhibitors have been approved by the Chinese government for the treatment of RET-rearranged non-small cell lung cancer. This study aimed to illustrate the efficacy and safety of selective RET inhibitors in a real-world clinical context in China.
Methods: Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring RET rearrangement and receiving RET tyrosine kinase inhibitors (RET-TKI) in the real world were enrolled in this retrospective study.
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study.
Future Oncol
December 2024
Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN 37203, USA.
We report clinical activity and safety of sitravatinib in patients with advanced cancer from basket cohorts with specific molecular alterations, in a Phase Ib study. Patients with advanced solid tumors harboring amplification, mutation, or rearrangement of , , , , , , , or received sitravatinib once daily. Primary end point was confirmed objective response rate (ORR).
View Article and Find Full Text PDFA case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation.
J Cardiothorac Surg
October 2024
Department of Thoracic Surgery, Beijing Chest Hospital, Beijing Tuberculosis and Thoracic Tumor Research Institute, Capital Medical University, No. 9 Beiguan Street, Tongzhou District, Beijing, 101149, China.
This case report details the successful treatment of a 68-year-old male patient with locally advanced RET-rearranged lung adenocarcinoma using neoadjuvant pralsetinib. The patient initially presented with a suspicious right upper lobe nodule, which was later diagnosed as lung adenocarcinoma following genetic testing that revealed a RET exon 12 fusion. After 2 months of neoadjuvant treatment with pralsetinib, a significant radiological response was observed, with a reduction in tumor size and metabolic activity.
View Article and Find Full Text PDFFirst-line selpercatinib for a patient with fusion-positive pulmonary large cell neuroendocrine carcinoma.
Respir Med Case Rep
September 2024
Department of Respiratory Medicine, NHO Tenryu Hospital, Hamamatsu, Japan.
Article Synopsis
- Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive form of non-small cell lung cancer that typically progresses quickly and often resists standard chemotherapy, leading to a poor prognosis.
- A case report highlights the successful use of selpercatinib, a kinase inhibitor, as a first-line treatment in a patient with advanced pulmonary LCNEC that contains a rare fusion gene.
- The findings emphasize the critical need for early genetic testing in patients with pulmonary LCNEC to allow for more effective targeted therapies.
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Cancer Lett
November 2024
Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan. Electronic address:
Article Synopsis
- Recent RET tyrosine kinase inhibitors (TKIs) show promise for treating RET-rearranged non-small cell lung cancer (NSCLC) and RET-mutated thyroid cancer, but resistance limits their effectiveness over time.* -
- A CRISPR/Cas9 screening identified genes related to drug-tolerant persister cells, revealing that loss of MED12 or MIG6 increases these resistant cells and activates EGFR, leading to treatment failure.* -
- Combining EGFR inhibitors with RET TKIs proved effective in overcoming resistance, and further experiments indicated that targeting either EGFR or RET enhances sensitivity to treatments in resistant cancer models.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!